Overview

Condition leukemia
Treatments sgi-110, idarubicin, cladribine
Phase phase 2
Sponsor M.D. Anderson Cancer Center
Collaborator Astex Pharmaceuticals
Start date April 2014
End date April 2026
Trial size 120 participants
Trial identifier NCT02096055, 2013-0843, NCI-2014-00981

Summary

The goal of this clinical research study is to compare different treatment schedules using the drug SGI-110 alone or in combination with other drugs. Researchers want to learn more about how these different treatment schedules may help to control AML. The safety of these treatments will also be studied.

Recruiting in the following locations…

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Induction Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 5 days. Patients who achieve a complete response (CR) or complete remission without platelet recovery (CRp) during induction may receive up to 24 months of maintenance therapy every 4 to 8 weeks. Maintenance Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 5 days.
sgi-110
Group A Induction Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 5 days. Maintenance Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 5 days. Group B Induction Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 10 days. Maintenance Phase: SGI-110 60 mg/m2 SQ daily for 10 days for 2 additional cycles, then daily for 5 days in later cycles. Group C Induction Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 5 days. Maintenance Phase: Same as Induction Phase. Group D Induction Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 5 days. Maintenance Phase: Same as Induction Phase.
(Experimental)
Induction Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 10 days. Patients who achieve a complete response (CR) or complete remission without platelet recovery (CRp) during induction may receive up to 24 months of maintenance therapy every 4 to 8 weeks. Maintenance Phase: SGI-110 60 mg/m2 SQ daily for 10 days for 2 additional cycles, then daily for 5 days in later cycles.
sgi-110
Group A Induction Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 5 days. Maintenance Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 5 days. Group B Induction Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 10 days. Maintenance Phase: SGI-110 60 mg/m2 SQ daily for 10 days for 2 additional cycles, then daily for 5 days in later cycles. Group C Induction Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 5 days. Maintenance Phase: Same as Induction Phase. Group D Induction Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 5 days. Maintenance Phase: Same as Induction Phase.
(Experimental)
Induction Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 5 days. Idarubicin 6 mg/m2 by vein daily for 2 days. Patients who achieve a completed response (CR) or complete remission without platelet recovery (CRp) during induction may receive up to 24 months of maintenance therapy every 4 to 8 weeks. Maintenance Phase: SGI-110 60 mg/m2 SQ daily for 5 days. Idarubicin 6 mg/m2 by vein on Day 1.
sgi-110
Group A Induction Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 5 days. Maintenance Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 5 days. Group B Induction Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 10 days. Maintenance Phase: SGI-110 60 mg/m2 SQ daily for 10 days for 2 additional cycles, then daily for 5 days in later cycles. Group C Induction Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 5 days. Maintenance Phase: Same as Induction Phase. Group D Induction Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 5 days. Maintenance Phase: Same as Induction Phase.
idarubicin Idamycin
Group C Induction Phase: Idarubicin 6 mg/m2 by vein daily for 2 days. Maintenance Phase: Idarubicin 6 mg/m2 by vein on Day 1.
(Experimental)
Induction Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 5 days. Cladribine 3 mg/m2 by vein daily for 5 days. Patients who achieve a complete response (CR) or complete remission without platelet recovery (CRp) during induction may receive up to 24 months of maintenance therapy every 4 to 8 weeks. Maintenance Phase: SGI-110 60 mg/m2 SQ daily for 5 days. Cladribine 2 mg/m2 by vein daily for 5 days.
sgi-110
Group A Induction Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 5 days. Maintenance Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 5 days. Group B Induction Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 10 days. Maintenance Phase: SGI-110 60 mg/m2 SQ daily for 10 days for 2 additional cycles, then daily for 5 days in later cycles. Group C Induction Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 5 days. Maintenance Phase: Same as Induction Phase. Group D Induction Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 5 days. Maintenance Phase: Same as Induction Phase.
cladribine Leustatin
Group D Induction Phase: Cladribine 2 mg/m2 by vein daily for 5 days. Maintenance Phase: Cladribine 2 mg/m2 by vein daily for 5 days.

Primary Outcomes

Measure
Complete Remission (CR) Rate
time frame: After 2, 4 week cycles cycles
Toxicity of 4 Different SGI-110 Single Agent and SGI-110 Based Combination Regimens.and SGI-110 Based Combination Regimens
time frame: After 2, 4 week cycles

Eligibility Criteria

Male or female participants at least 70 years old.

Inclusion Criteria: 1. Previously untreated AML patients, except those who have received prior therapy with hydroxyurea, single agent chemotherapy (e.g. decitabine), hematopoietic growth factors, biological or targeted therapies are allowed. 2. Age >/= 70 years 3. ECOG performance status /= 50 mL/min (estimated by the Cockcroft-Gault [C-G] formula). 6. Male patients must use an effective contraceptive method during the study and for a minimum of 8 weeks after study treatment. 7. Baseline LVEF >/= 40%. Exclusion Criteria: 1. Patients with >/= NYHA grade 3 heart disease as assessed by history and/or physical examination. 2. Patients who received more than one full course of prior hypomethylating agents azacitidine or decitabine 3. Have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo treatment. 4. Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment). 5. Pregnant or lactating patients. 6. Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results 7. Any concurrent malignancy (with the exception of exclusion # 8) 8. Exceptions to # 7: a) Patients with treated non-melanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia, regardless of the disease-free duration, are eligible for this study if definitive treatment for the condition has been completed; b) Patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease based on prostate-specific antigen (PSA) values are also eligible for this study if hormonal therapy has been initiated or a radical prostatectomy has been performed

Additional Information

Official title Four-Arm Randomized Phase II Study of SGI-110: 5 Days, Versus 10 Days, Versus 5 Days + Idarubicin, Versus 5 Days + Cladribine, in Previously Untreated Patients >/= 70 Years With Acute Myeloid Leukemia
Principal investigator Hagop Kantarjian, MD
Description Study Groups and Drug Administration: If you are found to be eligible to take part in this study, you will be randomly assigned (as in a roll of dice) to 1 of 4 study groups. You will have an equal chance of being assigned to each of the groups. Neither you nor the study staff can choose to which group you are assigned: - If you are in Group A, you will receive SGI-110 alone for 5 days. - If you are in Group B, you will receive SGI-110 alone for 10 days. - If you are in Group C, you will receive SGI-110 for 5 days and idarubicin for 2 days. - If you are in Group D, you will receive SGI-110 for 5 days and cladribine for 5 days. SGI-110 will be given 1 time each day through a needle under the skin. Idarubicin or cladribine will be given 1 time each day by vein over up to an hour. If you respond to the study drug(s) you can continue on the same schedule every 4 to 8 weeks, depending on how you react to the study drug(s). These 4-8 week periods will be called study cycles. The first few (up to 3) cycles will be called Induction Cycles. All cycles after this will be called Maintenance Cycles. The doses of the drugs, or number of times you receive them, may be reduced in the Maintenance Cycles. Study Visits: On Day 1 of every cycle (+/- 7 days), you will have a physical exam. Every week, blood (about 1-2 teaspoons) will be drawn for routine tests until any point that the disease appears to have gone away. After that, this blood draw will be every 2-8 weeks. The study staff will let you know when you will need these blood draws. On Day 15 (+/- 2 days) of Cycle 1, blood (about 2 teaspoons) will be drawn to check the status of the disease. On Day 28 (+/-7 days) of Cycle 1, you will have a bone marrow aspirate to check the status of the disease. After that, you will have a bone marrow aspirate every 2 weeks (+/- 7 days) until any point that the disease appears to not be responding. If the routine blood tests show that there is still leukemia, you may not need to have the bone marrow samples collected. If the disease has not appeared to have gone away after Cycle 2, the timing of your next bone marrow aspirate will depend on the results of your blood tests. Every 3-4 cycles (or whenever the doctor thinks it is needed), you will have either an ECHO or a MUGA to check your heart function. You will need to stay in Houston when you are receiving the study drug(s). When you have study visits in which you are not receiving study drug(s), these tests can be performed by your local doctor. Length of Study: You will receive the study drug(s) for up to 24 months. You will be taken off study if the doctor thinks it is in your best interest, if the disease gets worse, if you experience any intolerable side effects, or if you are unable to follow study directions. Your participation in this study will be over after the follow-up visits. Follow-up Visits: After your last dose of study drug, you will have follow-up visits. You will only have these visits if the disease has responded to the study drug(s). - Every month, blood (about 1 tablespoon) will be drawn for routine tests. These tests can be performed by your local doctor. - Every 6 months, you will return to Houston for a physical exam and blood (about 1 tablespoon) will be drawn for routine tests. This is an investigational study. Cladribine and idarubicin are FDA approved and commercially available for the treatment of several types of cancers affecting the blood, including different types of leukemia. SGI-110 is not FDA approved or commercially available. It is currently being used for research purposes only. Up to 120 patients will take part in this study. All will be enrolled at M.D. Anderson.
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by M.D. Anderson Cancer Center.